HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $1.25 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Neutral and maintains $1.25 price target.
Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Akebia Therapeutics Received Interim Response From The FDA To Appeal For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Owlet (NYSE:OWLT) shares rose 43.8% to $0.49 during Monday’s after-market session. At the close, Owlet’s trading volume…
Akebia Therapeutics Receives Interim Response To Appeal For Vadadustat For Treatment Of Anemia Due To Chronic Kidney Disease From FDA
Akebia met with the FDA in November to discuss its appeal and subsequently received a request for additional clarifying information from the Office of New Drugs, Center for Drug Evaluation and Research, which is deciding
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Akebia Therapeutics Earnings Preview
Akebia Therapeutics (NASDAQ:AKBA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Akebia Therapeutics will report an earnings per share (EPS) of $-0.17.
